99% B-Cell Depletion From an Antibody, Not CAR-T
Hinge Bio doses first patient with HB2198, a multispecific antibody targeting CD19 and CD20 for autoimmune disease.
Category Highly Important
Pancreatic Cancer Finally Has a Weak Spot. Here’s Who’s Going After It.
Revolution Medicines' Phase 3 daraxonrasib data validates a growing wave of early-stage companies attacking RAS.
The Push To Unlock Brain Cancer Is Heating Up. Time To Pay Attention.
In five weeks, 16 companies made moves against brain cancer. Gene therapies, oral pills, oncolytics, sonodynamic therapy. Something shifted.
Vivatides Raises $54M to Escape the Liver
Vivatides Therapeutics closes an oversubscribed $54M Series A for its extrahepatic RNA delivery platform.
Deck Bio’s T Cell Engagers Target Multiple Intracellular Targets. That’s a Big Deal.
Deck Bio launches a multi-target pMHC T cell engager platform that hits multiple intracellular cancer antigens with a single binder.
The Government Bet $15M That This Receptor Exists
Sparian Biosciences starts Phase 1 of SBS-147, a non-opioid pain drug funded by a $15M NIH HEAL grant.
83% Tumor Kill Rate. One Shot. Published in Nature.
Trogenix publishes preclinical GBM gene therapy data in Nature showing 83% complete tumor eradication from a single dose.
An Oral Pill for Glioblastoma. From Oslo.
Hemispherian doses first patients in a Phase 1/2a trial of GLIX1, a first-in-class oral TET2 activator for glioblastoma.
One Patient. One B Cell. A Whole New Playbook.
Immusoft presents the world's first engineered B cell therapy patient data at an FDA workshop.
$465M Partnership. 59% Response Rate. $5B Buyout.
Gilead Sciences acquires ADC developer Tubulis for up to $5 billion, turning a 2023 partnership into a full buyout.